NP has exercise options to implement the right to sell shares to finance payments; It has been exercised that way to pay Samsung and development (trials, fees, etc). They explicitly stated no intention of obtaining any debt for the benefit of protecting the share price to comply with the uplist to NYSE. Regarding to the new trials noticed, is very likly that this is a short fall due to option excersised to pay development cost in this noble manner.